RxDoctor Payments Data

James Simantirakis, DO

Family Medicine · Crown Point, INNPI 1114923927

Payments from drug & device makers

$781in general payments, 2019–2025

Across 55 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$157
  • AstraZeneca$156
  • Astellas Pharma US Inc$99
  • Boehringer Ingelheim$95
  • Novo Nordisk$65
  • Abbott$60
  • plus $149 from 5 others

What the payments were for

  • Food & beverage$77599%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$781 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$101,894
Medicare patients
464
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$157,754
JardianceEmpagliflozin37$62,598
TrulicityDulaglutide34$55,480
JanuviaSitagliptin Phosphate30$49,656
EliquisApixaban36$36,058
Breo ElliptaFluticasone/Vilanterol45$34,654
FarxigaDapagliflozin Propanediol20$30,540
XareltoRivaroxaban11$17,064
MounjaroTirzepatide12$12,606
Spiriva RespimatTiotropium Bromide13$12,142
Atorvastatin Calcium594$4,607
SymbicortBudesonide/Formoterol Fumarate11$4,567
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,300
Levothyroxine Sodium376$3,527
SynthroidLevothyroxine Sodium50$2,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$157,754105 claims
Boehringer IngelheimJardiance, Spiriva Respimat$95$74,74150 claims
Lilly USA, LLCTrulicity, Mounjaro$27$68,08646 claims
MerckJanuvia$12$49,65630 claims
PfizerEliquis$157$36,05836 claims
AstraZenecaFarxiga, Symbicort$156$35,10831 claims
Johnson & JohnsonXarelto$50$17,06411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →